Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma

Table 1 Clinical characteristics of The Cancer Genome Atlas Live Hepatocellular Carcinoma sample training and test groups (n = 343)

Covariates	Sub type	Entire TCGA-LIHC, n (%)	Test group, n (%)	Training group, n (%)	P value
Age (yr)	≤ 65	216 (62.97)	103 (60.23)	113 (65.70)	0.3493
	> 65	127 (37.03)	68 (39.77)	59 (34.30)
Gender	Female	110 (32.07)	59 (34.50)	51 (29.65)	0.3971
	Male	233 (67.93)	112 (65.50)	121 (70.35)
Grade	G1	53 (15.45)	27 (15.79)	26 (15.12)	0.3
	G2	161 (46.94)	85 (49.71)	76 (44.19)
	G3	112 (32.65)	54 (31.58)	58 (33.72)
	G4	12 (3.50)	3 (1.75)	9 (5.23)
	Unknown	5 (1.46)	2 (1.17)	3 (1.74)
Stage	Stage I	161 (46.94)	81 (47.37)	80 (46.51)	0.9079
	Stage II	77 (22.45)	39 (22.81)	38 (22.09)
	Stage III	80 (23.32)	38 (22.22)	42 (24.42)
	Stage IV	3 (0.87)	2 (1.17)	1 (0.58)
	Unknown	22 (6.41)	11 (6.43)	11 (6.40)
T	T1	168 (48.98)	86 (50.29)	82 (47.67)	0.5683
	T2	84 (24.49)	42 (24.56)	42 (24.42)
	T3	75 (21.87)	37 (21.64)	38 (22.09)
	T4	13 (3.79)	4 (2.34)	9 (5.23)
	Unknown	3 (0.87)	2 (1.17)	1 (0.58)
M	M0	245 (71.43)	118 (69.01)	127 (73.84)	0.9551
	M1	3 (0.87)	2 (1.17)	1 (0.58)
	Unknown	95 (27.70)	51 (29.82)	44 (25.58)
N	N0	239 (69.68)	111 (64.91)	128 (74.42)	0.9081
	N1	3 (0.87)	2 (1.17)	1 (0.58)
	Unknown	101 (29.45)	58 (33.92)	43 (25.00)

T: Tumor; N: Lymph node; M: Metastasis. The P value is indicated for the chi-square test and Kruskal-Wallis test among the three groups.